ABSTRACT. The ICR-derived glomerulonephritis (ICGN) mouse, a novel inbred mouse strain with a hereditary nephrotic syndrome, develops severe anemia associated with chronic renal failure. To reveal the pathogenic mechanism of anemia in ICGN mice, we subcutaneously administered recombinant human erythropoietin (rhEPO; 5 IU/mouse/day) or saline for 5 days to ICGN mice. In terminal-stage ICGN mice with severe anemia, rhEPO significantly increased hematocrit (Ht), red blood cells (RBC) and hemoglobin levels. Endogenous EPO levels in peripheral blood were reduced by rhEPO injection. No histopathological changes in bone marrow and kidneys w ere induced by rhEPO injection. Insufficiency of EPO may cause anemia in ICGN mice. KEY WORDS: anemia associated with chronic renal failure, erythropoietin, hereditary nephrotic mouse (ICGN).
The Institute of Cancer Research (ICR)-derived glomerulonephritis (ICGN) mouse, an inbred mouse strain with a hereditary nephrotic syndrome, is considered to be a good model of human idiopathic nephrotic syndrome [9] . Homozygous ICGN mice show the typical symptoms of nephrosis [10] [11] [12] and exhibit severe glomerular and tubulointestitial fibrosis [14] . Age-dependent increases in apoptotic cell and proliferating cell densities were also observed in the kidneys of ICGN mice [15] . Renal deterioration eventually leads to death as a result of chronic renal disorder (CRD). Moreover, ICGN mice develop a marked anemia with the deterioration of renal function [16] . Anemia associated with chronic renal failure is a major subsequent symptom that appears in the earlier stages of renal disease. It is a normochromic and normocytic anemia with hypoplastic bone marrow. The anemia associated with chronic renal failure is initially mild and inconsequential, however, ultimately it directly affects quality of life [3, 13] .
Twenty week-age homozygous ICGN mice were prepared by mating homozygous males (nep/nep) and heterozygous females (nep/-), and age-and sex-matched ICR mice, were purchased from Clea Japan (Tokyo, Japan) as healthy controls. They received humane care as outlined in the "Guide for the Care and Use of Laboratory Animals" (Kyoto University Animal Care Committee according to NIH No. 86-23; revised 1999). Peripheral blood samples were obtained from the cervical vein under ether anesthesia and used for hematological and biochemical analyses. Hematological analyses were performed using an automatic counter (K-4500; Sysmex Co., Kobe, Japan), as were serum biochemical analyses (Fuji Drichem 3500V; Fuji Film, Tokyo, Japan), according to the manufacturer's instructions.
Based on serum creatinine (sCre) levels, ICGN mice were categorized into three groups (latent, progressing and terminal) [14] [15] [16] . Briefly, ICGN mice with less than 0.34 mg/dl of sCre (mean plus SD of healthy ICR mice: 0.27 plus 0.07) were categorized as being in the latent stage. ICGN mice with 0.35-0.54 mg/dl (twice the mean of ICR mice) and those with more than 0.55 mg/dl were classified as being in the progressing and terminal stages, respectively. Then, they were sacrificed under deep ether anesthesia, and the kidneys, livers, spleens and thigh bones were removed, and fixed in 10% neutral-buffered formalin, pH 7.4 (Wako Pure Chimical, Osaka, Japan), for histopathological analyses. Terminal stage-ICGN mice exhibit systemic edema as well as pale looking ears and tails. As shown in Fig. 1 , a negative correlation was obtained between sCre and hematocrit (Ht) values in ICGN mice (n=52), in contrast to the stable values in ICR mice (n=51), indicating that the ICGN mouse is an appropriate model for anemia associated with chronic renal failure.
Several causes of renal anemia have been proposed, but the primary cause is considered to be a lack of erythropoiein (EPO), which is a glycoprotein and classified as a hematopoietic cytokine [6] . Wide variation in serum EPO levels were reported in patients with CRD, and the serum EPO level is low for the degree of anemia [1, 2, 17] . In clinical cases, treatment with recombinant human EPO (rhEPO) improves the anemic condition. Anemic patients with renal failure (hemoglobin less than 12 g/dl and hematocrits less than 33%) are candidates for rhEPO therapy, and subcutaneous injection of rhEPO (50-300 IU/kg, three times per week) is applied with careful management [3, 4, 8] .
In the present study, we examined whether administering rhEPO improves anemia in ICGN mice or not, to reveal the pathogenic mechanism of anemia in this model. ICGN mice were subcutaneously injected with rhEPO (5 IU/mouse/day, approximately 150 IU/kg/day; Sigma Aldrich Chemicals, St. Louis, MO, U.S.A.), according to the clinical guidelines [3, 4, 8] , or saline (0.1 ml/mouse; vehicle control) for 5 days (n=17 mice in each group). ICR mice injected with saline were used as healthy controls. Twenty-four hours after the final administration, hematological and biochemical features were measured to evaluate the effect of rhEPO. Studen t's t-test was p erfo rm ed fo r biochem ica l a nd hematological data using the StatView IV program (Abacus Concepts, Berkely, CA, U.S.A.) on a Macintosh computer. Differences of P<0.05 were considered to be significant.
As shown in Table 1 , significant increases of Ht (50.5 and 51.0% in progressing and terminal stages, respectively), red blood cell count (873.6 and 941.6 × 10 4 cells/µl in progressing and terminal stages, respectively), and hemoglobin concentration (20.3, 19.4 and 21.6 g/dl, in latent, progressing and terminal stages, respectively) were found in ICGN mice injected with rhEPO compared with ICGN mice injected with saline. With the increase of Ht, RBC and hemoglobin levels, mean corpuscular volume (MCV; 58.5 and 59.0 fl, in progressing and terminal stages, respectively) also increased in ICGN mice injected with rhEPO. The present results indicate that the administration of rhEPO significantly improved the anemic condition in ICGN mice. Moreover, rhEPO injected into ICGN mice lowered endogenous EPO levels in peripheral plasma (119.9 ± 68.0 and 105.2 ± 95.8 mIU/ml in vehicle and rhEPO groups, respectively, represents mean ± SD in progressing stage), as measured by a sandwich-ELISA method using two monoclonal antibodies (R2 and R6 clones) against murine EPO according to Masuda et al. [7] , suggesting that the regulatory system for the blood EPO level remains intact in ICGN mice.
Paraffin sections of bone marrows and kidneys were stained with Wright-giemsa and hematoxylin and eosin for histopathological evaluation. No obvious histological changes were seen in the bone marrows or kidneys of ICGN mice injected with saline (vehicle) compared with rhEPO (Fig. 2) .
Thus, the administration of rhEPO significantly improved the anemic condition in ICGN mice, but no histopahological changes in bone marrow or kidneys were induced. An effective response against rhEPO without histological damage indicates that ICGN mice retain some erythropoietic ability in bone marrow, including the EPO receptor (EPOR)-mediated pathway. In vitro studies have revealed that EPO regulates the proliferation, differentiation and survival of erythroid progenitor cells in bone marrow [5, 6] . EPO deficiency is a major cause of anemia associated with chronic renal failure, though the molecular mechanism involved is still unknown. The improvement by rhEPO treatment in ICGN mice suggests that the lack of EPO directly relates to the anemia occurring in these mice. Thus, the ICGN mouse is a suitable model for elucidating the precise cause of the anemia associated with chronic renal failure. 
